论文部分内容阅读
背景:同型半胱氨酸已成为动脉粥样硬化的独立危险因子,它可能通过破坏内皮细胞的结构和功能从而导致动脉粥样硬化。目的:探讨同型半胱氨酸对老年冠心病患者纤溶酶活性的影响。设计:以冠心病患者为研究对象,健康人群为对照组的病例-对照。单位:一所大学医院的综合科及心内科。对象:本研究于首都医科大学附属北京朝阳医院综合科及心内科完成。选择2001-12/2003-8本院心内科及综合科门诊及住院患者177例,根据冠状动脉造影结果分为:冠心病组91例,其中男50例,女41例,平均年龄(66±6)岁;冠状动脉造影阴性组86例,其中男43例,女43例,平均年龄(60±6)岁。正常对照组为同期于本院门诊体检的健康中年人85例,其中男43例,女42例,平均年龄(55±5)岁。方法:收集外周血,检测血浆中的组织型纤溶酶原激活剂、纤溶酶原激活物抑制剂1和血管性血友病因子的活性,用酶免疫试验法测同型半胱氨酸,并计算纤溶酶原激活物抑制剂1/组织型纤溶酶原激活剂活性比值。主要观察指标:血清同型半胱氨酸水平及血浆组织型纤溶酶原激活剂、纤溶酶原激活物抑制剂1、血管性血友病因子活性,纤溶酶原激活物抑制剂1/组织型纤溶酶原激活剂的比值。结果:冠状动脉病变组同型半胱氨酸,纤溶酶原激活物抑制剂1,纤溶酶原激活物抑制剂1/组织型纤溶酶原激活剂,
BACKGROUND: Homocysteine has become an independent risk factor for atherosclerosis and may contribute to atherosclerosis by disrupting the structure and function of endothelial cells. Objective: To investigate the effect of homocysteine on plasmin activity in elderly patients with coronary heart disease. Design: Patients with coronary heart disease as the research object, the healthy population as the control group case-control. Unit: General Hospital and Cardiology of a University Hospital. Subjects: The study was completed at the Department of Cardiology and Cardiology, Beijing Chaoyang Hospital, Capital Medical University. According to the result of coronary angiography, there were 91 cases of coronary heart disease, including 50 males and 41 females, with an average age of 66 ± 6) years old; coronary angiography negative group of 86 patients, 43 males and 43 females, mean age (60 ± 6) years. In the normal control group, 85 healthy middle-aged people were examined in our hospital during the same period, including 43 males and 42 females, with an average age of (55 ± 5) years. Methods: Peripheral blood was collected and the activity of tissue plasminogen activator, plasminogen activator inhibitor 1 and von Willebrand factor in plasma were measured. Homocysteine, And calculate plasminogen activator inhibitor 1 / tissue plasminogen activator activity ratio. MAIN OUTCOME MEASURES: Serum levels of homocysteine and plasma tissue plasminogen activator, plasminogen activator inhibitor 1, von Willebrand factor activity, plasminogen activator inhibitor 1 / Tissue plasminogen activator ratio. Results: Homocysteine, plasminogen activator inhibitor 1, plasminogen activator inhibitor 1 / tissue plasminogen activator,